Navigation Links
Avanir Pharmaceuticals Announces Enrollment Of First Patient In Study Of AVP-923 For The Treatment Of Agitation In Patients With Alzheimer's Disease
Date:9/4/2012

ALISO VIEJO, Calif., Sept. 4, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the enrollment of the first patient in study AVR-131. The study is a Phase II clinical trial investigating the use of AVP-923 for the treatment of agitation in patients with Alzheimer's disease.

"Alzheimer's disease can cause a person to exhibit marked behavioral changes that are difficult for caregivers to manage. These symptoms can include agitation, hostility, anger, and aggression, with most patients exhibiting some or all of these symptoms during the course of the disease," said Jeffrey Cummings, MD, Professor of Neurotherapeutics and Drug Development in the Neurological Institute, Cleveland Clinic. "As the disease progresses, behavioral symptoms often increase in frequency and severity. With no approved therapies for agitation associated with dementia, managing these symptoms can be challenging. This trial is an important initial step in potentially providing a therapy to help manage symptoms of agitation in Alzheimer's disease."

The objectives of this proof of concept study are to evaluate the safety, tolerability, and efficacy of AVP-923 for the treatment of agitation in Alzheimer's patients. The trial is a multicenter, randomized, double-blind, placebo-controlled study that is expected to enroll up to 200 Alzheimer's patients in the United States. Eligible patients will be randomized to receive either AVP-923 or placebo for 10 weeks. The main efficacy measure is the Neuropsychiatric Inventory or NPI. Secondary outcome measures include assessments of disease severity, behavioral abnormalities, cognition, activities of daily living, quality of life and caregiver strain. Standard safety assessments will also be conducted.

Jeffrey Cummings, MD is a paid consultant of Avanir Pharmaceuticals, Inc. In addition, Dr. Cummings is the inventor of the
'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Avanir Pharmaceuticals To Present At Two Investor Conferences In August
2. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Third Quarter Financial Results And Conference Call
3. Avanir Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference
4. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Second Quarter Financial Results And Conference Call
5. Avanir Pharmaceuticals To Present at Three Conferences In May
6. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
7. Elevation Pharmaceuticals Presents Positive Phase 2b Results for EP-101 in COPD Patients at the European Respiratory Society Annual Congress
8. Lexicon Pharmaceuticals To Present At The Stifel Nicolaus 2012 Healthcare Conference
9. Novation Supports New Development in the U.S. Biosimilar Pharmaceuticals Market
10. Arena Pharmaceuticals to Present at Upcoming Investor Conferences
11. Isis Pharmaceuticals Demonstrates The Potential Of Single-Stranded RNA-Like Antisense Technology To Activate The RNAi Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... FLINT, Mich. , Aug. 31, 2015  Diplomat Pharmacy, ... pharmacy, has announced that Phil Hagerman , Chairman & ... four upcoming investor conferences. Mr. Hagerman and ... 2015 Healthcare Conference in Boston on ... Mr. Hagerman and Mr. Whelan are also scheduled to participate ...
(Date:8/31/2015)... 2015 BioLight Life ... ("BioLight" or the "Company"), a firm that invests ... and cancer diagnostics, today announced that its cancer ... several new genetic markers with high potential to ... with bisphosphonate drugs and was able to repeat ...
(Date:8/31/2015)... , Aug. 31, 2015  Soligenix, Inc. ... biopharmaceutical company developing products that address unmet medical ... biodefense, announced today it has completed enrollment of ... Review Committee (DRC) earlier this year, into the ... a first-in-class innate defense regulator (IDR) and is ...
Breaking Medicine Technology:Diplomat to Participate in Upcoming Investor Conferences 2BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 2BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6
(Date:8/31/2015)... ... August 31, 2015 , ... ... management device that could effectively deliver oxygen with a lower risk of failure," ... better way, I invented the Adam Device." , The Adam Device offers a ...
(Date:8/31/2015)... Tennessee (PRWEB) , ... August ... ... of Lifestyle Medicine (ACLM), the nation’s medical professional association for physicians and ... in conjunction with the Lifestyle Medicine Foundation, announced today the establishment of ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... MeYou ... recently enhanced its mobile walking app, Walkadoo , by including an in-app step ... goals that adapt to each person’s walking habits. Rather than broadly assign every Walkadoo ...
(Date:8/31/2015)... ... 2015 , ... There’s big news for ZendyHealth , a Los Angeles-based ... Consumer driven health plans (CDHPs) are a growing phenomenon, and ZendyHealth has brought on ... company, and another to answer customers’ questions directly. , John Young, CEO of Consumerdriven, ...
(Date:8/31/2015)... ... 31, 2015 , ... The Brooks Group, a global sales ... department devoted to helping organizations identify and keep the best talent both inside ... Brooks Group believes in offering a solution that goes beyond simply providing assessments ...
Breaking Medicine News(10 mins):Health News:InventHelp® Client's Invents Medical Device to Restore Respiratory Function (BGF-905) 2Health News:Nominations Sought for Awards Recognizing Exemplary Contribution to the Field of Lifestyle Medicine 2Health News:Nominations Sought for Awards Recognizing Exemplary Contribution to the Field of Lifestyle Medicine 3Health News:Walkadoo™ Walking Program Now Includes In-app Step Tracker 2Health News:ZendyHealth Adds Two Prestigious Consumer Driven Health Plan (CDHP) Experts 2Health News:ZendyHealth Adds Two Prestigious Consumer Driven Health Plan (CDHP) Experts 3Health News:The Brooks Group Introduces Talent Management Division 2Health News:The Brooks Group Introduces Talent Management Division 3
... question results of small Polish study , , TUESDAY, Jan. ... left main coronary artery appeared to give better short-term results ... experts cast some doubt on the clinical value of the ... University of Silesia, compared results of surgery versus stenting in ...
... Educational teleconference on medical therapies to feature Mayo Clinic ... ... 29 Crohn,s disease and ulcerative,colitis patients, caregivers, and healthcare professionals ... Medications?" This,free, live, interactive teleconference through the Crohn,s & Colitis,Foundation will ...
... confused with ... at least one other drug, ROCKVILLE, Md., Jan. 29 ... (USP),revealed that more than 1,400 commonly used drugs are involved in errors,linked ... the MEDMARX report, 1.4% of the errors resulted in patient harm,including seven ...
... Arcadian Health Plan, Inc., a,leading provider of ... its benefits for 2008 and expanded into the,state ... successful rollouts in,Oklahoma, Georgia, South Carolina and Maine., ... premiums, free annual,physicals and flu shots, dental benefits, ...
... Plan, Inc.,a leading provider of Medicare Advantage health plans ... expanded into the,state of Oklahoma. This comes on the ... Maine., Highlights of these plans include $0 premiums ... benefits, and an ever-expanding,provider and hospital network., "We,ve ...
... in Homes and Cars, GENEVA, Jan. 29 It,s ... world,s youth - breathe air polluted,by tobacco smoke. People who ... others to a dangerous mix of toxins including nicotine, carbon,monoxide, ... children to chronic health risks:, -- Increases a ...
Cached Medicine News:Health News:Stents Slightly Better Than Bypass for Blocked Left Coronary Artery 2Health News:Stents Slightly Better Than Bypass for Blocked Left Coronary Artery 3Health News:Interactive Teleconference on Inflammatory Bowel Disease for Patients, Caregivers, and Healthcare Professionals 2Health News:U.S. Pharmacopeia 8th Annual MEDMARX(R) Report Indicates Look-Alike/Sound-Alike Drugs Lead to Thousands of Medication Errors Nationwide 2Health News:U.S. Pharmacopeia 8th Annual MEDMARX(R) Report Indicates Look-Alike/Sound-Alike Drugs Lead to Thousands of Medication Errors Nationwide 3Health News:Bright Options for Medicare Beneficiaries in Louisiana 2Health News:Expanded Options for Medicare Beneficiaries in Oklahoma 2Health News:Global Initiative To Protect Children From Secondhand Smoke 2Health News:Global Initiative To Protect Children From Secondhand Smoke 3
Control Plasma for Assays of Unfractionated Heparins (UH) using Anti-Xa Methodon STA© Analyzers....
... Normal and Abnormal ... Assays of vWF, D-dimer ... on STA© Analyzers. For ... vWF (#0518),STA© LIATEST© D-DI ...
CRP high sensitivity calibrator series...
Inquire...
Medicine Products: